When patients are vaccinated with synthetic tumor-specific or tumor-associated peptides or combinations of peptides, these peptides are presented on human leukocyte antigen (HLA) molecules on the cell surface, inducing and activating CD4+ and CD8+ T cells, resulting in powerful therapeutic effects. The gene discussed is CD8A; the disease is neoplasm.